Cardiac Transplant Rejection
📧 Sign up to get email alerts when something new happens for Cardiac Transplant Rejection.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-06-08Clinical Trial Update: A Study of AI in Cardiac Transplant in Echocardiographic Analysis (ORACLE)
A Mayo Clinic-sponsored clinical trial (ORACLE) is evaluating AI-enabled echocardiography for detecting cardiac transplant rejection and is …
-
CLINICAL_TRIALS research · 2025-04-06Clinical Trial Update: Magnetic Resonance Elastography as a Method to Estimate Stiffness of Soft Tissues
This clinical trial investigates using magnetic resonance elastography to estimate tissue stiffness in conditions like heart failure and liv…
-
CLINICAL_TRIALS trial_result · 2024-10-29Clinical Trial Update: Utility of Donor-Derived Cell Free DNA in Association With Gene Expression Profiling
Clinical trial evaluating donor-derived cell-free DNA in combination with gene expression profiling for assessing cardiac transplant rejecti…
-
FDA approval · 2024-08-13FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (VistaPharm, LLC)
FDA approves a supplemental application for mycophenolate mofetil (VistaPharm, LLC), endorsing a generic product for prevention of organ tra…
-
CLINICAL_TRIALS research · 2024-07-25Clinical Trial Update: A Pilot Study Evaluating the Potential of 18F Fluorodeoxyglucose PET-CT Imaging in Diagnosing Cardiac Rejection. [NA]
A pilot study is evaluating whether 18F-FDG PET-CT imaging can help diagnose rejection in heart transplant patients; the trial is not yet re…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-05-09FDA Approved: MYCOPHENOLIC ACID — Supplemental Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories' supplemental application for mycophenolic acid, authorizing continued marketing of this generic product.
-
FDA approval · 2021-10-22FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approves a supplemental application for CELLCEPT (mycophenolate mofetil) submitted by Genentech, Inc.
-
FDA approval · 2021-05-04FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for mycophenolate mofetil submitted by Mylan Pharmaceuticals, updating labeling and/or indicatio…
-
FDA approval · 2021-04-21FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for CELLCEPT (mycophenolate mofetil) from Genentech, Inc.
-
CLINICAL_TRIALS research · 2018-04-17Clinical Trial Update: Heart TIMING - Heart Transplantation IMagING
This is a clinical trial update for the Heart TIMING study evaluating imaging-guided heart transplantation using magnetic resonance imaging;…
-
CLINICAL_TRIALS trial_result · 2017-03-08Clinical Trial Update: Home Electrocardiogram (ECG) Monitoring After Heart Transplantation
The completed trial evaluated home ECG monitoring after heart transplantation to monitor for rejection and QT interval variation.
-
FDA approval · 2015-10-30FDA Approved: MYCOPHENOLATE MOFETIL — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for mycophenolate mofetil filed by Mylan Pharmaceuticals Inc. The action relates to the approved gen…
-
FDA approval · 2014-01-23FDA Approved: CELLCEPT — Supplemental Application (Genentech, Inc.)
The FDA approved Genentech's supplemental application for Cellcept (mycophenolate mofetil), under NDA 050722, confirming a change/update via…